Table 1 Relationship between the expression of PRAF3 and clinical features
clinical features | esophageal squamous cell carcinoma | |||
|---|---|---|---|---|
| Â | PRAF3-positive n (%) | PRAF3-negative n (%) | test | P |
Total | 24 | 33 | Â | Â |
Age (year) | Â | Â | Â | Â |
< 60 | 13/24 (54.2) | 19/33 (57.6) | 0.0656 | 0.7979 |
≥ 60 | 11/24 (45.8) | 14/33 (42.4) |  |  |
Gender | Â | Â | Â | Â |
Male | 17/24 (70.8) | 25/33 (75.8) | 0.1738 | 0.6768 |
Female | 7/24 (29.2) | 8/33 (24.2) | Â | Â |
Pathological grading | Â | Â | Â | Â |
Well | 11/24 (45.9) | 6/33 (18.2) | 5.9991 | 0.0498 |
Moderately | 8/24 (33.3) | 12/33 (36.4) | Â | Â |
Poorly | 5/24 (20.8) | 15/33 (45.4) | Â | Â |
Tumor location | Â | Â | Â | Â |
Upper 1/3 middle 1/3 | 15/24 (62.5) | 23/33 (70.0) | 0.3239 | 0.5693 |
Lower 1/3 | 9/24(37.5) | 10/33 (30.0) | Â | Â |
Tumor stage | Â | Â | Â | Â |
T1/T2 | 13/24 (54.2) | 8/33 (24.2) | 5.347 | 0.0208 |
T3/T4 | 11/24 (45.8) | 25/33 (75.8) | Â | Â |
Lymph node metastasis | Â | Â | Â | Â |
Negative | 14/24 (58.3) | 10/33 (30.3) | 4.4785 | 0.0343 |
Positive | 10/24 (41.7) | 23/33 (69.7) | Â | Â |